Peptides
Bronchogen: lung-tissue culture is not a breathing treatment
What is it?
Bronchogen is marketed as a short peptide bioregulator for lung and airway tissue. The name suggests tissue specificity, but a targeted effect in a laboratory culture is not the same as a targeted therapeutic effect in a person. [1]
What do studies show?
A Russian-language paper tested bronchogen alongside several other bioregulators on organotypic explants from young and old rat tissues. At 0.05 ng/mL in culture, the authors reported stimulation in corresponding tissue explants. No one in this study had asthma, COPD, lung injury, or another clinical outcome measured. The authors’ suggestion of future clinical use is a hypothesis, not a demonstrated treatment. [1]
Safety
Human inhaled or injectable exposure, product purity, and adverse events are not established by an explant study. Respiratory symptoms should be evaluated with established diagnostic and treatment methods.
DOSE STATUS
How much?
EVIDENCE CONTEXT
Why?
The cited evidence does not establish a dose for this use or product.
The study’s 0.05 ng/mL was a concentration placed into a tissue-culture dish, not a human dose. No effective and safe adult Bronchogen amount or attributable exact-product anecdotal protocol has been verified. A vial’s milligrams do not answer that question. [1]
Sources & further reading
- Original rat organotypic tissue-culture bioregulator study (opens in a new tab)pubmed.ncbi.nlm.nih.gov